Prosecution Insights
Last updated: November 12, 2026
Application No. 18/697,878

COMPOSITIONS AND METHODS FOR LEVODOPA DELIVERY

Non-Final OA §112
Filed
Apr 02, 2024
Priority
Oct 06, 2021 — provisional 63/262,162 +1 more
Examiner
TRUONG, QUANGLONG N
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nanomerics Ltd.
OA Round
2 (Non-Final)
79%
Grant Probability
Favorable
2-3
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
519 granted / 660 resolved
+18.6% vs TC avg
Strong +23% interview lift
Without
With
+23.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
720
Total Applications
across all art units

Office Action

§112
DETAILED CORRESPONDENCE Status of Application The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The claim set and remarks filed on 6/9/2026 are acknowledged. Claims 1,5,18,22-23,28-30,37-38,44,46,50,52-54,59,63 and 81 are pending. Response to Arguments Applicant’s arguments filed 6/9/2026 have been fully considered and are persuasive in overcoming the prior art rejections. The previous rejections under 35 USC 103 are now withdrawn. Claims 1,5,18,22-23,28-30,37-38,44,46,50,52-54,59,63 and 81 are free of the art. However, upon further consideration of the claim language, examiner makes the new ground of rejection below. Since the new grounds of rejection are not necessitated by amendment, this action is made NON-FINAL. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1,5,18,22-23,28-29 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 is indefinite for reciting the phrase “Parkinson’s-like symptoms”, which is unclear because the phrase is not objectively defined in the specification. The specification does not provide guidance to objectively define what can qualify as “Parkinson’s-like symptoms”. Claims 5,18,22-23,28-29 are included in this rejection because they do not correct for the defect of the claims from which they depend. Appropriate correction is required. Conclusion Claims 30,37-38,44,46,50,52-54,59,63 and 81 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QUANGLONG N TRUONG whose telephone number is (571)270-0719. The examiner can normally be reached on 8:00am-5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QUANGLONG N TRUONG/Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Apr 02, 2024
Application Filed
Mar 09, 2026
Non-Final Rejection mailed — §112
Jun 09, 2026
Response Filed
Aug 31, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788850
A Drug Coating Formulation for a Sirolimus Coated Balloon Catheter
2y 7m to grant Granted Nov 10, 2026
Patent 12788717
MAGNETIC FERRITIC NANOCOMPOSITE
2y 0m to grant Granted Nov 10, 2026
Patent 12773486
PROCESS FOR REMOVING IONS FROM BODILY FLUIDS USING SMALL MOLECULE METAL CHELATORS AND METALLATE ION EXCHANGE COMPOSITIONS
5y 2m to grant Granted Oct 27, 2026
Patent 12773439
BOTANICAL EXTRACTION
3y 7m to grant Granted Oct 27, 2026
Patent 12765545
PREPARATION OF A DRY BIOMASS EXTRACT RICH IN POLYPHENOLS
3y 11m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.2%)
Moderate
PTA Risk
Based on 660 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month